FDA approves Tecentriq for bladder ctDNA

On May 15, the U.S. Food and Drug Administration approved Tecentriq, also known as atezolizumab, for adults with muscle-invasive bladder cancer after cystectomy whose blood shows circulating tumor DNA-based molecular residual disease on an FDA-authorized test. Genentech said the approval also covers the subcutaneous formulation Tecentriq Hybreza, and Natera said its Signatera CDx received simultaneous authorization as the companion diagnostic. (gene.com) The decision ties adjuvant immunotherapy to a post-surgery blood test rather than to pathology stage alone. (roche.com) It gives doctors a labeled way to treat only the patients whose blood still shows molecular evidence of residual disease. ### Which bladder cancer patients are covered by the new approval? Adults with muscle-invasive bladder cancer are eligible after bladder removal surgery if they have ctDNA molecular residual disease detected in blood by an FDA-authorized test, according to the FDA-linked company announcements. The approval is for adjuvant treatment, meaning therapy given after surgery to reduce the risk of recurrence. Cystectomy patients were monitored with serial ctDNA testing for up to one year after surgery in the pivotal trial, Genentech said. The surveillance phase of IMvigor011 included 761 people who underwent repeat testing, and those with detectable ctDNA were then randomized to Tecentriq or placebo. (gene.com) ### What evidence did the FDA rely on? Roche reported in October 2025 that the phase III IMvigor011 trial met its endpoints in ctDNA-positive patients after surgery. In that study, Tecentriq reduced the risk of disease recurrence or death by 36% and reduced the risk of death by 41% versus placebo. Median disease-free survival was 9.9 months with Tecentriq versus 4.8 months with placebo, and median overall survival was 32.8 months versus 21.1 months. (gene.com) The New England Journal of Medicine published the IMvigor011 results in October 2025, according to search records and company statements. Genentech said the FDA based its decision on those phase III data. (gene.com) ### Why is the blood test central to this decision? Signatera CDx was approved as the companion diagnostic for use with adjuvant atezolizumab in this setting, Natera said on May 15. The test is intended to identify patients with muscle-invasive bladder cancer who are ctDNA-positive after surgery and may benefit from treatment. The FDA’s companion diagnostic device list defines such tests as tools that provide information essential for the safe and effective use of a corresponding therapeutic product. (roche.com) In this case, the drug label and the test approval are linked: treatment is indicated for patients whose molecular residual disease is identified by an FDA-authorized assay. (nejm.org) ### What did investigators and companies say about the result? Thomas Powles, lead principal investigator of IMvigor011 and chair of Barts Cancer Centre, said in Natera’s release that the trial and approval show molecular residual disease testing guiding “when to treat” and “whom to treat.” Roche Chief Medical Officer Levi Garraway said in the company’s October 2025 statement that serial ctDNA testing may advance bladder cancer treatment by pairing a precision diagnostic with immunotherapy. (natera.com) Solomon Moshkevich, president of clinical diagnostics at Natera, called the approval “a major milestone” for precision oncology in the company’s statement. (fda.gov) That characterization came from Natera; the FDA page available publicly did not include a separate narrative approval announcement for this label update. ### What changes in practice now? The label creates a post-cystectomy pathway in which patients can be monitored with an FDA-authorized ctDNA test and offered Tecentriq if residual disease is detected in blood. Genentech said the approval is the first for a ctDNA-guided therapy, and Natera said it is the first companion diagnostic approval in blood-based molecular residual disease. (natera.com) May 15 is also the date both companies said the drug and test decisions took effect. The next practical step is uptake by oncologists, urologists and pathology workflows using the newly authorized Signatera CDx alongside Tecentriq or Tecentriq Hybreza in eligible post-cystectomy patients. (gene.com) (natera.com)